InvestorsHub Logo

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating
profile icon
lanny9 Free
12/08/23 10:25 AM
profile icon
adam69 Free
12/08/23 9:37 AM
profile icon
all4weed Free
12/08/23 1:52 AM
profile icon
Abundance88 Free
12/06/23 10:44 PM
profile icon
all4weed Free
12/06/23 6:10 PM
profile icon
Chuckmunk Free
12/06/23 3:40 PM
profile icon
lanny9 Free
12/06/23 1:16 PM
profile icon
all4weed Free
12/06/23 3:20 AM
profile icon
Shawking Free
12/04/23 12:30 PM
profile icon
Shawking Free
11/28/23 9:25 PM
profile icon
Abundance88 Free
11/28/23 9:42 AM
profile icon
damAcon1 Free
11/27/23 12:18 PM
profile icon
Shawking Free
11/27/23 11:59 AM
Bullish
Bullish
profile icon
Shawking Free
11/21/23 1:17 PM
profile icon
harlem111 Free
11/16/23 3:26 PM
profile icon
all4weed Free
11/16/23 2:07 PM
profile icon
Shawking Free
11/14/23 9:29 PM
profile icon
adam69 Free
11/10/23 12:27 PM
profile icon
all4weed Free
11/08/23 10:55 PM
profile icon
harlem111 Free
11/08/23 3:17 PM
profile icon
MasterBidder Free
11/08/23 1:06 PM
profile icon
PotsandPans420 Free
11/08/23 11:33 AM
profile icon
all4weed Free
11/08/23 1:11 AM
profile icon
hdhick Free
11/07/23 5:55 PM
profile icon
Shawking Free
11/07/23 1:03 PM
profile icon
hdhick Free
11/06/23 10:30 PM
profile icon
Monksdream PremiumMember
11/05/23 1:08 PM
profile icon
Shawking Free
11/03/23 2:32 PM
profile icon
MasterBidder Free
11/02/23 2:02 PM
profile icon
boo boo PremiumMember
11/02/23 9:24 AM
profile icon
mazzjazz Free
11/01/23 6:11 PM
profile icon
Abundance88 Free
10/31/23 6:52 PM
profile icon
Gaffer222 Free
10/31/23 7:53 AM
profile icon
hdhick Free
10/30/23 7:28 PM
profile icon
MasterBidder Free
10/24/23 3:11 PM
profile icon
MasterBidder Free
10/24/23 10:49 AM

Lexaria Bioscience Corp (LEXX) RSS Feed

Followers
216
Posters
549
Posts (Today)
0
Posts (Total)
34280
Created
10/02/07
Type
Free
Moderators


Lexaria Bioscience Announces new DehydraTECH Innovation, Files New Patents

https://www.youtube.com/watch?v=YSROQ7DlIJ4

Welcome to Lexaria Bioscience Corp.

Lexaria Bioscience Corp. (CSE:LXX; OTCQX:LXRP) has developed and out-licenses its disruptive and cost-effective DehydraTECH™ technology that promotes healthier administration methods, lower overall dosing and higher effectiveness of ingestible drugs and other beneficial molecules.

Lexaria’s DehydraTECHTM delivery technology is protected by a robust suite of patents granted or pending worldwide and is proven effective in multiple international studies in greatly assisting rapidity and quantity of absorption of a range of lipophilic (i.e., fat-soluble), bioactive molecules.  By significantly enhancing the performance and experience with oral ingestion, Lexaria’s DehydraTECH delivery technology offers a viable and often healthier alternative to other delivery methods for bioactive substances in widespread use today such as inhalational delivery through smoking.

 

About DehydraTECH

Lexaria’s patented technology, DehydraTECH™ delivers these important benefits:

Masks taste/odor

Eliminates the strong tastes/odors of lipophilic compounds, without the need for unwanted sugar or sweeteners

Reduces time of onset

Effects are felt within 15-20 min vs. 60-120 min.

Avoids first-pass liver metabolism

Initial testing indirectly evidences DehydraTECH may deliver ingested molecules through the lymphatic system instead of being subject to immediate “first pass” liver exposure, potentially mitigating unwanted side effects and reducing liver biotransformation.

Increases bio-absorption

Bio-absorption increases up to 3 – 10X, to equate or exceed that of other routes of administration like inhalational delivery.

 

DehydraTECH Commercial Applications

Lexaria’s DehydraTECH™ is designed specifically for formulating and delivering lipophilic (i.e. fat-soluble) drug payloads. It is patented or patent-pending for use with a broad range of bioactive molecules, including but not limited to:
 

Nicotine

Lexaria Bioscience Corp. (“Lexaria”) has formed the Lexaria Nicotine Corp. as its exclusive worldwide nicotine business unit. More than 89% of all nicotine that is consumed worldwide is delivered through smoking cigarettes. Approximately 6,000,000 deaths per year around the world are attributed primarily to the delivery of nicotine through the act of smoking according to the Centers for Disease Control and Prevention. Of note: “…it is primarily the toxins and carcinogens in tobacco smoke – not the nicotine – that cause illness and death.” (U.K. National Institute for Health and Care Excellence [NICE]). As many as 69% of U.S. adult smokers want to quit smoking and 43% of US adult smokers have attempted to quit in any twelve-month period. Lexaria postulates that delivery of nicotine to satisfy current demand, utilizing our patented DehydraTECH technology in common food and consumer product formats, could shift demand away from smoking cigarettes. However, ingestion of nicotine is challenging because it is poorly tolerated by the human gastrointestinal system and then significantly metabolized by the liver, thereby diminishing its overall effectiveness through edibles. Lexaria’s DehydraTECH technology offers a means to formulate ingestible product formats of nicotine and/or its analogs with higher bioavailability performance possibilities due to the benefits of our technology.
 

Pharmaceuticals

Lexaria is developing a patent suite with supporting intellectual property in the pharmaceutical sector that will supply significant long-term strategic growth potential.  Lexaria Pharmaceutical Corp. is the 100%-owned subsidiary that has obtained exclusive worldwide rights to Lexaria’s patent portfolio related to pharmaceutical applications. Currently within this business unit resides the IP for Non-Steroidal Anti-Inflammatories (NSAIDs), Vitamins, hormone treatments utilizing estrogen or testosterone, phosphodiesterase inhibitors (PDE5). Additional molecules of interest could be added to this unit over time.

According to Statista.com, the global pharma industry was worth $1,105 billion in 2016, and the US pharma industry alone spent over $71 billion in 2017 on R&D: a larger R&D expenditure than the entire gross revenues of many other business sectors.. Lexaria Pharmaceutical Corp. is implementing a strategy of reinforcing its IP-suite to sufficient degree to begin partnering within this dynamic industry.
 

HempCo

The Lexaria Hemp Co. holds exclusive global rights to the Lexaria patent portfolio related to hemp-based applications. Lexaria’s DehydraTECH technology is designed to deliver functional ingredients within hemp in oral product formats with significantly enhanced palatability, speed of effectiveness and potency as a viable and healthier alternative to conventional inhalational (i.e. smoking or vaping) administration practices. Extensively evaluated through invivo, invitro, and human clinical studies, one of the most extensive databases in the world has been collected by Lexaria related to hemp-based ingredients empowered with our DehydraTECH technology. In 2018, the World Anti Doping Agency (WADA) for the first time ever exempted cannabidiol from hemp from its list of restricted substances on its International Standards Prohibited List of substances.
 

Other

Lexaria CanPharm Corp, a Canadian corporation, owns exclusive global rights to Lexaria’s intellectual property as it is applied to psychotropic bioactive molecules that act upon human CB1 and CB2 receptors in those areas of the world where it is permissible to do so. Substances that act upon these receptors and systems in the human body that affect pain, inflammation, anxiety and depression, and have also been shown to have utility against cancer and neurodegenerative conditions. Lexaria’s ground-breaking 2018 research that proved many-fold improvements in delivering an active ingredient across the blood-brain-barrier could have disruptive potential within this business sector as well as all others where Lexaria is active.
 

 

Research

Overview

The safety and effectiveness of Lexaria’s DehydraTECH™ technology has been studied in a series of controlled and well designed in vitro and in vivo human focus studies, examining factors such as total bioabsorption directly and indirectly through surrogate biomarkers, time to onset of effectiveness, flavor appeal and quality of effectiveness.  Studies to-date have focused on cannabinoid applications where Lexaria is most advanced commercially, although research is underway for the other bioactive compounds named in Lexaria’s patent portfolio and described under Commercial Applications.

Pre-Clinical Research into Lexaria’s DehydraTECH™

An in vitro absorption study was performed to assess unidirectional CBD permeability using a human epi-intestinal tissue model with various formulations in the presence of simulated intestinal fluid.  The study was designed to, as closely as possible, mimic intestinal absorption as it would occur in a live subject.  Samples of Lexaria’s commercially available CBD-fortified ViPova™ black tea were administered in the model compared with concentration-matched CBD control preparations that lacked Lexaria’s patented formulation and process enhancements.  The study showed as much as a 499% improvement, on average, in intestinal tissue permeability with the ViPova™ black tea formulation relative to a concentration-matched CBD control preparation without any Lexaria technology enhancements.  The study also showed a 325% improvement, on average, in intestinal tissue permeability comparing the ViPova™ black tea preparation to a concentration-matched CBD control preparation that utilized Lexaria`s dehydration synthesis processing methodology but lacked its fatty acid ingredient incorporation, demonstrating the power of the Lexaria technology as a whole (see Figure 1).

 

 

Clinical Research into Lexaria's DehydraTECH™

Following this study, a series of independent, well designed, well controlled human focus studies were undertaken corroborating Lexaria’s in vitro performance findings.  A study in healthy volunteers (n=6) suggested as much as a 5-10X increase in CBD absorption, which was assessed indirectly through